Most Read Articles
4 days ago
Combining the DASH (Dietary Approaches to Stop Hypertension) diet with low sodium intake reduces systolic blood pressure (SBP) in individuals with pre- and stage 1 hypertension, with progressively higher reductions at greater levels of baseline SBP, a recent study has shown.
Tristan Manalac, 2 days ago
Major depressive disorder (MDD) appears to be more prevalent in females than in males, particularly in those who are divorced or widowed, a recent study from Singapore has found.
3 days ago
Tadalafil may not be effective for reducing the decline in ambulatory ability in boys with Duchenne muscular dystrophy (DMD), as shown in a recent study.
6 days ago
Hydrochlorothiazide (HCTZ) appears to significantly increase the risks of nonmelanoma skin cancer (NMSC), particularly squamous cell carcinoma (SCC), a recent study has shown.

Biological outdoes conventional synthetic DMARD for psoriatic arthritis

12 Aug 2017
A new therapy is now available to patients who cannot tolerate DMARDs.

The use of biological disease-modifying antirheumatic drugs (bDMARD) is associated with a minimal disease activity (MDA) status and remission in patients with psoriatic arthritis (PsA) as compared to conventional synthetic (cs)DMARD, according to a recent study.

Additionally, it appears that Psoriatic Arthritis Disease Activity Score (PASDAS) ≤1.9 and MDA 7/7 are stringent remission criteria.

Researchers enrolled patients with PsA (n=109) categorized using the CASPAR criteria and with >6 months follow-up treated with first csDMARD and bDMARD. They assessed disease activity using composite indices tailored for PsA, such as the Disease Activity Index for Psoriatic Arthritis (DAPSA), clinical (c)DAPSA, PASDAS, MDA 5/7 and MDA 7/7.

Remission was identified by DAPSA and cDAPSA score ≤4, MDA 7/7, and PASDAS ≤1.9. MDA and low disease activity (LDA) criteria were identified by MDA 5/7, DAPSA score ≤14, cDAPSA score ≤13 and PASDAS <3.2.

Of the patients enrolled, 79 were receiving stable treatment with bDMARD and 30 with csDMARD.

In general, there were 28 patients (25.6 percent) in cDAPSA remission, 23 (21.1 percent) in DAPSA remission, 19 (17.4 percent) in MDA 7/7 and 13 (11.9 percent) in PASDAS ≤1.9. In addition, 54 patients (49.5 percent) were in MDA 5/7, 80 (73.3 percent) in DAPSA LDA, 79 (72.3 percent) in cDAPSA LDA and 38 (34.8 percent) in PASDAS LDA.

Compared with patients treated with csDMARD, those treated with bDMARD had significantly lower median DAPSA, cDAPSA and PASDAS score.

According to researchers, there are several methods available to define remission or LDA in a complex disease such as PsA.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
4 days ago
Combining the DASH (Dietary Approaches to Stop Hypertension) diet with low sodium intake reduces systolic blood pressure (SBP) in individuals with pre- and stage 1 hypertension, with progressively higher reductions at greater levels of baseline SBP, a recent study has shown.
Tristan Manalac, 2 days ago
Major depressive disorder (MDD) appears to be more prevalent in females than in males, particularly in those who are divorced or widowed, a recent study from Singapore has found.
3 days ago
Tadalafil may not be effective for reducing the decline in ambulatory ability in boys with Duchenne muscular dystrophy (DMD), as shown in a recent study.
6 days ago
Hydrochlorothiazide (HCTZ) appears to significantly increase the risks of nonmelanoma skin cancer (NMSC), particularly squamous cell carcinoma (SCC), a recent study has shown.